Celiac Disease Genetic Risk

The GlutenID test uses qualitative genotyping to detect clinically relevant variants in the genomic DNA of adults from buccal (cheek) cells for the purpose of reporting and interpreting celiac genetic health risk (GHR). This test is not intended to diagnose celiac disease. Your ethnicity may affect the relevance of the report and how your celiac genetic health risk results are interpreted. The variants included in this report are supported by Level 1 (the highest) level of evidence. The celiac risk variants are most common in people of northern European descent. The celiac GHR report describes if a person has variants associated with a higher risk of developing celiac disease, but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Warnings & Limitations: This report does not include variants in other genes linked to celiac disease and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact celiac risk. The GlutenID test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action. The intended use of the GlutenID Test does not include prenatal testing, cancer predisposition, pharmacogenomic assessment, or determination of autosomal dominant genetic variants. For important information and limitations regarding genetic health risk reports, visit Targeted-Genomics.com/about-the-test/.